MedTrace Logo

Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322

NCT07312799 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2025-12-31

No results posted yet for this study

Summary

To evaluate the pharmacokinetic interactions of AD-2321, AD-2322 in healthy adult volunteers.

Conditions

Interventions

DRUG

Treatment A(AD-2321)

AD-2321 Oral Tablet

DRUG

Treatment B(AD-2322)

AD-2322 Oral Tablet

DRUG

Treatment C(AD-2321+AD-2322)

AD-2321 Oral Tablet+AD-2322 Oral Tablet

Sponsors & Collaborators

  • Addpharma Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-27
Primary Completion
2026-02-11
Completion
2026-02-26

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07312799 on ClinicalTrials.gov